These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 15296860)

  • 1. Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance.
    Andes D
    Drug Resist Updat; 2004 Jun; 7(3):185-94. PubMed ID: 15296860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside.
    Hope WW; Drusano GL
    Clin Microbiol Infect; 2009 Jul; 15(7):602-12. PubMed ID: 19673971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics: relation to antimicrobial resistance.
    Rybak MJ
    Am J Infect Control; 2006 Jun; 34(5 Suppl 1):S38-45; discussion S64-73. PubMed ID: 16813981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics in the development of antifungal compounds.
    Andes D
    Curr Opin Investig Drugs; 2003 Aug; 4(8):991-8. PubMed ID: 14508883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of antifungals.
    Andes D
    Infect Dis Clin North Am; 2006 Sep; 20(3):679-97. PubMed ID: 16984875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic/pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine.
    McKellar QA; Sanchez Bruni SF; Jones DG
    J Vet Pharmacol Ther; 2004 Dec; 27(6):503-14. PubMed ID: 15601444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Issues in antifungal susceptibility testing.
    Johnson EM
    J Antimicrob Chemother; 2008 Jan; 61 Suppl 1():i13-8. PubMed ID: 18063599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifungal PK/PD considerations in fungal pulmonary infections.
    Lepak AJ; Andes DR
    Semin Respir Crit Care Med; 2011 Dec; 32(6):783-94. PubMed ID: 22167406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations.
    Andes D; Craig WA
    Clin Microbiol Infect; 2005 Nov; 11 Suppl 6():10-7. PubMed ID: 16209701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies.
    Gumbo T
    Curr Opin Infect Dis; 2007 Dec; 20(6):587-91. PubMed ID: 17975408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro antifungal susceptibility patterns of dermatophyte strains causing tinea unguium.
    Sarifakioglu E; Seçkin D; Demirbilek M; Can F
    Clin Exp Dermatol; 2007 Nov; 32(6):675-9. PubMed ID: 17714532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of a serum-based antifungal susceptibility assay to predict the in vivo efficacy of novel echinocandin compounds.
    Maki K; Matsumoto S; Watabe E; Iguchi Y; Tomishima M; Ohki H; Yamada A; Ikeda F; Tawara S; Mutoh S
    Microbiol Immunol; 2008 Aug; 52(8):383-91. PubMed ID: 18667037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact.
    Kanafani ZA; Perfect JR
    Clin Infect Dis; 2008 Jan; 46(1):120-8. PubMed ID: 18171227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections.
    Burgess DS
    Clin Infect Dis; 2005 Feb; 40 Suppl 2():S99-104. PubMed ID: 15712103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro evaluation of griseofulvin against clinical isolates of dermatophytes from Isfahan.
    Chadeganipour M; Nilipour S; Havaei A
    Mycoses; 2004 Dec; 47(11-12):503-7. PubMed ID: 15601457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
    Burkhardt O; Lehmann C; Madabushi R; Kumar V; Derendorf H; Welte T
    J Antimicrob Chemother; 2006 Oct; 58(4):822-9. PubMed ID: 16885180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial susceptibility breakpoints: PK-PD and susceptibility breakpoints.
    Ambrose PG
    Treat Respir Med; 2005; 4 Suppl 1():5-11. PubMed ID: 15846151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on antifungal drug resistance mechanisms of Aspergillus fumigatus.
    Chamilos G; Kontoyiannis DP
    Drug Resist Updat; 2005 Dec; 8(6):344-58. PubMed ID: 16488654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic/pharmacodynamic modeling in drug research and development.
    Derendorf H; Lesko LJ; Chaikin P; Colburn WA; Lee P; Miller R; Powell R; Rhodes G; Stanski D; Venitz J
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1399-418. PubMed ID: 11185661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of pharmacokinetics/pharmacodynamics of antibacterials in their dosing regimen selection.
    Scaglione F; Paraboni L
    Expert Rev Anti Infect Ther; 2006 Jun; 4(3):479-90. PubMed ID: 16771624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.